Highlights the lack of prospective randomized trials for treating hypertension in end-stage renal disease and recommends following National Kidney Foundation guidelines.
Supports NKF guidelines for ESRD hypertension; leaves open optimal targets and agents without prospective RCTs.
The prevalence of hypertension is extremely high in end-stage renal disease, and is a probable contributor to the epidemic of cardiovascular disease in end-stage renal disease. However, the paucity of prospective, randomized clinical trials makes it difficult to precisely define treatment strategies. Therefore, at present time the guidelines developed by the National Kidney Foundation's Cardiovascular Disease Task Force should be followed.
No takes yet. Share an insight, caveat, or question.
Zager et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: